Literature DB >> 31350109

Hepatitis C virus core antigen is cost-effective in community-based screening of active hepatitis C infection in Taiwan.

Jing-Houng Wang1, Chien-Hung Chen2, Chia-Ming Chang3, Wen-Chin Feng4, Chih-Yi Lee5, Sheng-Nan Lu6.   

Abstract

BACKGROUND AND
PURPOSE: Hepatitis C virus (HCV) core antigen is highly sensitive and specific in viremic HCV diagnosis. This study evaluated the cost-effectiveness of HCV core antigen (HCVcAg) in community-based screening for active HCV infection.
METHODS: Between 2017/07 and 2018/07, community-based screenings for active HCV infection with two-step (anti-HCV for screening and HCVRNA for diagnosis) and one-step processes (HCVcAg for screening and diagnosis) were conducted in two districts in Kaohsiung City. While HCVcAg test was positive at ≥3 fmol/L, the lowest level of HCV-RNA detection was 12 IU/mL. We analyzed the cost-effectiveness of two algorithms in identifying active HCV infection.
RESULTS: There were two large-scale screenings using the two-step process with a total of 2452 residents enrolled; while six hundred and forty-four residents participated in continuous small-scale screening with the one-step process. The prevalence of anti-HCV and positive HCVcAg was 3.4% and 2.8%. The viremic rate was 1.4% and 2.8% for two- and one-step processes (p < 0.001). While all positive HCVcAg were viremic, 42.4% of positive anti-HCV patients had viremia. The positive predictive value was 42.2% and 100% for two- and one-step processes in detecting active HCV infection (p < 0.001). In identifying one active HCV infection, the cost was $755.3 and $711.1 dollars for two- and one-step processes respectively.
CONCLUSION: Compared to the two-step process in community-based screening, continuous screening with the HCVcAg test as a one-step tool for active HCV infection was cost-effective in areas with low seroprevalence of HCV in Taiwan.
Copyright © 2019 Formosan Medical Association. Published by Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Community-based screening; Cost-effectiveness; Hepatitis C virus core antigen

Year:  2019        PMID: 31350109     DOI: 10.1016/j.jfma.2019.07.011

Source DB:  PubMed          Journal:  J Formos Med Assoc        ISSN: 0929-6646            Impact factor:   3.282


  6 in total

1.  Clinical utility of hepatitis C virus core antigen assay in the monitoring of direct-acting antivirals for chronic hepatitis C.

Authors:  Sheng Feng Lin; Shui-Yi Tung; Kuo-Liang Wei; Chien-Hung Chen; Tsung-Hui Hu; Chien Heng Shen; Te-Sheng Chang; Wei-Ming Chen; Chih-Wei Yen; Jing-Houng Wang; Chao-Hung Hung; Sheng-Nan Lu
Journal:  PLoS One       Date:  2020-03-03       Impact factor: 3.240

2.  Role of hepatitis C virus core antigen assay in hepatitis C care in developing country.

Authors:  Ouafa Kallala; Saoussen Kacem; Imene Fodha; Bruno Pozzetto; Trabelsi Abdelhalim
Journal:  Egypt Liver J       Date:  2021-09-18

3.  Community-Based Screening for Hepatitis B and C Infectivity Using Two Quantitative Antigens to Identify Endemic Townships.

Authors:  Wei-Cheng Huang; Yu-Chen Lin; Po-Ju Chen; Nien-Tzu Hsu; Chia-Ling Tu; Te-Sheng Chang; Chao-Hung Hung; Kwong-Ming Kee; Wen-Hua Chao; Sheng-Nan Lu
Journal:  Viruses       Date:  2022-02-01       Impact factor: 5.048

4.  Time to complete hepatitis C cascade of care among patients identified during mass screening campaigns in rural Rwanda: a retrospective cohort study.

Authors:  Innocent Kamali; Fabienne Shumbusho; Dale A Barnhart; Françoise Nyirahabihirwe; Jean de la Paix Gakuru; Wellars Dusingizimana; Esdras Nizeyumuremyi; Placide Habinshuti; Stephen Walker; Jean Damascene Makuza; Janvier Serumondo; Gallican Nshogoza Rwibasira; Jean d'Amour Ndahimana
Journal:  BMC Infect Dis       Date:  2022-03-21       Impact factor: 3.090

5.  Village-to-village screening for hepatitis B and C using quantitative HBsAg and anti-HCV testing with reflex HCV core antigen tests in the remote communities of a resource-rich setting: a population-based prospective cohort study.

Authors:  Te-Sheng Chang; Kao-Chi Chang; Wei-Ming Chen; Nien-Tzu Hsu; Chih-Yi Lee; Yu-Chih Lin; Wei-Cheng Huang; Wen-Nan Chiu; Jin-Hung Hu; Tung-Jung Huang; Mei-Yen Chen; Sheng-Nan Lu
Journal:  BMJ Open       Date:  2021-07-07       Impact factor: 2.692

6.  Liver Disease Screening and Hepatitis C Virus Elimination in Taiwan Rural Indigenous Townships: Village-By-Village Screening and Linking to Outreach Hepatology Care.

Authors:  Hui-Min Tien; Tai-Chung Cheng; Hsiao-Chu Lien; Kuei-Fei Yang; Cherng-Gueih Shy; Yu-Ling Chen; Nien-Tzu Hsu; Sheng-Nan Lu; Jing-Houng Wang
Journal:  Int J Environ Res Public Health       Date:  2022-03-10       Impact factor: 3.390

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.